[Molecular diagnosis in hematologic malignancies].
Recent advances in molecular diagnosis in the hematological laboratory have greatly contributed to the diagnosis and treatment of hematologic malignancies, such as leukemia and lymphoma. The pathogenesis of leukemia and lymphoma has been disclosed by the analyses of genetic abnormalities in patients; abnormal gene expression may induce derangement in the control of cellular proliferation. Based on these genetic abnormalities, gene-targeted therapy has been introduced as a new approach to treating hematologic malignancies. We discuss here the usefulness of the molecular diagnosis in clinical hematology.
Nara
Nobuo
N
Tokyo Medical and Dental University, Bunkyo-ku, Tokyo 113-8519.
D000970:Antineoplastic Agents / Q000627:therapeutic use; D001549:Benzamides; D015973:Gene Expression Regulation, Leukemic; D018390:Gene Targeting; D015316:Genetic Therapy / Q000379:methods; D006801:Humans; D000068877:Imatinib Mesylate; D007938:Leukemia / Q000175:diagnosis* / Q000235:genetics / Q000628:therapy; D025202:Molecular Diagnostic Techniques; D018365:Neoplasm, Residual / Q000175:diagnosis; D010879:Piperazines; D011379:Prognosis; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D011743:Pyrimidines / Q000627:therapeutic use; D014212:Tretinoin / Q000627:therapeutic use
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D014212:Tretinoin; D000068877:Imatinib Mesylate; D011505:Protein-Tyrosine Kinases